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KRAS Mutation 
Spectrum Notably 
Diverges between 
Non-small Cell 
Lung and Colorectal 
Carcinomas
To the Editor:
We read the article entitled “A sys-
tematic review and Canadian consensus 
recommendations on the use of biomark-
ers in the treatment of non-small cell 
lung cancer” by Ellis et al.1 with major 
interest and would like to address com-
ment on it. Since 2008, clinical research 
studies on non-small cell lung cancer 
(NSCLC) have allowed the transfer of 
EGFR gene mutations testing to the rou-
tine analysis for predicting the response 
to tyrosine kinase inhibitors (TKI) such 
as gefitinib or erlotinib. Therefore, inter-
est in individualizing patient treatment 
to maximize clinical benefit has become 
a focus of scientific investigation. The 
presence of a translocation involving the 
anaplastic lymphoma kinase (ALK) gene 
with EML4 is now admitted to confer 
a remarkable sensitivity to crizotinib, a 
specific ALK TKI. In contrast, mutations 
activating the KRAS oncogene are gener-
ally reported as associated with a lack of 
response to EGFR TKI in several studies, 
but the mechanism remains unclear and 
controversial thus insufficient to adopt 
KRAS mutation detection as a consen-
sual tool for therapeutic decision.2–5
When entering into details of 
KRAS somatic mutations, their predic-
tive value in stage IV colorectal cancer 
(CRC) patients for treatment with EGFR 
monoclonal antibodies has been estab-
lished. RAS mutations are found in 40 
to 45% of metastatic colorectal adeno-
carcinomas, and the mutation spectrum 
has been extensively studied, mutations 
involving codon 12 or 13 of KRAS being 
found in 40% of cases and the remain-
ing 5% being spread over KRAS codons 
61 and 146 or NRAS. on KRAS codons 
12 and 13, seven mutations have been 
recognized as the most frequent, leading 
to the development of commercial kits 
focusing on these seven mutations. The 
use of these kits has been extended to 
other tumor types, in particular NSCLC, 
as able to predict the absence of EGFR 
mutation or ALK translocation as these 
events have been reported as mutually 
exclusive, instead of predicting a specific 
resistance to EGFR TKI. Also, the strat-
egy of drug development moves toward 
the ability of specifically targeting the 
RAS pathway.
Involved in somatic mutations 
detection in our Cancer Institute, we 
evaluated the possibility to use those kits 
targeted on the seven most frequent KRAS 
mutations that are less expensive and time 
consuming when compared with nonse-
lective techniques like sequencing. From 
June 2006 to September 2011, a consec-
utive series of 1642 histologic samples 
of metastatic CRC patients has been 
referred to the bio-pathologic depart-
ment for sequencing the KRAS codons 
12 and 13 mutation status before enroll-
ing patients in cetuximab-based proto-
cols, and 633 mutations were recorded 
(39%). Since January 2009, an additional 
762 samples from patients affected by 
NSCLC was screened using the same 
approach, leading to the identification 
of 186 mutations (24.4%) (Table 1). 
When comparing the mutation spectra of 
these two tumor types, no major differ-
ence in frequencies is observed except 
for c.37G>T and for delins mutations 
that are found in 15 of CRC, i.e., 2.3% 
of mutated samples, and 27 of NSCLC, 
i.e., 14.5% of mutated samples. These 
mutations are not precisely or unreliably 
detected using the commercial kits. If the 
proportion of missed mutations is quite 
low in CRC, it is much higher in NSCLC 
and cannot be neglected. In those cases, 
there is a risk to treat with an ineffective 
therapy, and in the future these patients 
could lack chance of having a RAS-
targeted therapy.
In summary, meta-analyses on 
molecular biomarkers usually put 
together results derived from clinical 
studies based on heterogeneous molec-
ular approaches, and subsequent con-
flicting results lead to preclude the use 
of potential markers in medical prac-
tice. When transferring new molecular 
markers in routine testing, we would 
like to recommend a scrupulous con-
sideration when choosing the detection 
technique.
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In Response:
We read with interest the letter 
from Compagnone et al.,1 entitled “KRAS 
mutation spectrum notably diverges from 
non–small-cell lung cancer to colorectal 
carcinomas.” The authors describe their 
institutional experience with KRAS test-
ing in colorectal cancer and non small 
cell lung cancer (NSCLC). In particular, 
they report that the distribution of KRAS 
mutations in NSCLC is different from 
that in colorectal cancer, with a higher 
proportion of c.37G . T and delins 
mutations of codon 15. These muta-
tions may not reliably be detected by 
commercial kits. The authors stress the 
importance of laboratory technique in 
selecting which molecular tests to imple-
ment in practice.
We agree with the authors that 
quality assurance for molecular test-
ing is a critical issue, but question 
the relevance of this in the context of 
KRAS mutation testing in NSCLC. The 
importance of KRAS testing in NSCLC 
is clearly different from that of KRAS 
testing in colorectal cancer, where data 
support KRAS as a predictive biomarker 
for epidermal growth factor recep-
tor (EGFR)-directed therapy. There is 
a need for consistent and reliable data 
demonstrating the predictive value of a 
biomarker before it is incorporated into 
routine clinical practice. The authors 
state that KRAS mutations are gener-
ally associated with lack of response 
to EGFR tyrosine kinase inhibitors. 
However, as stated both in our review2 
and that of Roberts et al.,3 the available 
data do not support the routine use of 
KRAS testing as a predictive biomarker 
for lung cancer.
The point is also made that KRAS 
mutation testing may be used to predict 
for the absence of an EGFR mutation or 
anaplastic lymphoma kinase transloca-
tion. This point was discussed at length 
when formulating our consensus recom-
mendations. Ultimately, it was felt there 
was not a strong rationale to perform 
KRAS testing to predict the results of 
EGFR testing. We believe the data bet-
ter support EGFR mutation testing in all 
patients with advanced NSCLC and non-
squamous histology. The findings from 
Compagnone et al., that nearly 15% of 
KRAS mutations might be missed dur-
ing commercial testing rather than direct 
sequencing, if anything, reinforces this 
point of view. Although KRAS testing 
might be helpful in a research setting to 
select patients for clinical trials of rast 
sarcoma (RAS)-directed therapy, there 
may be potential harm from a strategy 
that routinely employs KRAS testing. 
Given the conflicting information about 
the utility of RAS testing, there is poten-
tial for patients with KRAS mutations 
not to receive an EGFR tyrosine kinase 
inhibitor. However, available data from 
trials such as the Sequential Tarceva in 
Unresectable NSCLC trial of mainte-
nance erlotinib4 and the IRESSA Non-
Small Cell Lung Cancer Trial Evaluating 
Response and Survival against Taxotere 
trial5 comparing gefitinib versus doc-
etaxel showed similar survival outcomes 
for RAS mutated and wild-type patients.
In conclusion, we are of the opin-
ion that the findings of Campognone et 
al. are interesting, but do not change our 
recommendation against the routine use 
of RAS testing in patients with NSCLC.
Peter M. Ellis, MBBS, PhD
Juravinski Cancer Centre
Hamilton, ontario, Canada
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TABLE 1. KRAS Exon 2 Mutation Spectrum in Colorectal (CRC) and Non-small Cell Lung (NSCLC) Cancers
Mutationa c.34G>A c.34G>T c.34G>C c.35G>A c.35G>C c.35G>T c.37G>A c.37G>T c.38G>A Delinsb
CRC 32 57 9 218 39 129 1 4 133 11
 5 9 1.4 34.4 6.1 20.4 0.1 0.6 21 1.7
NSCLC 1 72 1 28 13 30 0 14 14 13
 0.5 38.7 0.5 15 7 16.1 0 7.5 7.5 7
aEnriched tumor zones were selected from fixed material on HE-stained sections and DNA was extracted from three pinches per sample using the DNA QIAamp® micro-kit 
(Qiagen). Exon 2 of the KRAS gene (NM_033360) was analyzed by sequencing after PCR amplification using primer pair 5AAGGCCTGCTGAAAATGACTG/5CAAAGAATGGTC
CTGCACCAG. Sequences were compared with the reference sequences using the SeqScape® software. The variants were encoded according to the Human Genome Variation Society 
recommendations (http://www.hgvs.org/mutnomen).
bDelins mutations involving codons 12 and 13 in CRC are c.34_35delinsAT (2), c.34_35delinsTT (4), c.34_35delinsCT (1), c.34_35delinsTA (2), c.38_39delinsTT (1), and 
c.38_39delinsAT (1) and in NSCLC are c.34_35delinsTT (5), c.38_39delinsTT (1), c.34_35delinsAT (1), c.34_35delinsAA (1), c.34_35delinsTA (1), c.37_38delinsTA (1), 
c.34_35delinsTC (1), c.33_34delinsCT (1), and c.36_37delinsGT.
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